Custom service
Special Antigen Peptides Service
Prepare special antigen peptides — mutated, modified or multi-epitope — for immunology work
Teams come to this service when they need to prepare special antigen peptides — mutated, modified or multi-epitope — for immunology work. We typically start from mutation-site synthesis, add citrullination and other PTM antigens where the application demands it, and close the loop with multi-epitope concatemer design so the final antigen peptide(s) with purity and identity QC behaves consistently across lots.
Design reviews are part of the schedule, not an extra. Sequence, spacer architecture and analytical strategy are signed off before the first synthesis run, which is why the 3–6 weeks timeline holds in practice.
RA and autoimmune citrullinated antigens
Tumour neoantigen peptides
Antigens requiring patient-matched material
Sequences where a recombinant expression route is objectively cheaper and faster
Release specification is fixed at quotation: standard >95% by HPLC, >98% for assay-critical material. Long chains (>60 residues) are additionally confirmed by MS/MS sequence coverage, and truncated-deletion species are quantified, not just summarized.
Service Highlights
- Mutation-site synthesis as the default route, with citrullination and other PTM antigens held as a proven fallback
- Multi-epitope concatemer design worked into the design where the application requires it
- Sequence difficulty analysis (aggregation risk, motif hazards) is done before synthesis, and the route is chosen around it
- Analytical confirmation of every intermediate before the final release
- Microwave-assisted coupling and double-coupling are applied automatically where the sequence demands them
- Antigen peptide(s) with purity and identity QC delivered with a complete conjugation or synthesis certificate
How the work runs
Sequence analysis
Special Antigen Peptides Service is analyzed for aggregation risk, motif hazards and puri?cation difficulty before a route is quoted.
Route selection
Fmoc solid-phase, fragment ligation or hybrid solution-phase is selected and documented.
Assembly
The chain is built with mutation-site synthesis applied where the sequence demands it, with double-coupling at hazard sites.
Cleavage & crude QC
Crude material is characterized so purification targets are set on data, not hope.
Purification
RP-HPLC (and ion-exchange where needed) delivers the agreed purity; fractions are pooled on MS confirmation.
Release
Antigen peptide(s) with purity and identity QC is documented with the full analytical package and released.
Specifications & timeline
- Turnaround
- 3–6 weeks
- Typical scale
- 0.1 mg – 10 g per sequence
- Chemistry options
- mutation-site synthesis; citrullination and other PTM antigens; multi-epitope concatemer design
- Deliverable
- Antigen peptide(s) with purity and identity QC
- QC package
- HPLC purity, ESI/MALDI MS, MS/MS confirmation for long chains
- Shipping
- Ambient with desiccant; blue ice for modified or sensitive peptides
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.